Literature DB >> 9349579

Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy.

D I Shulman1, I Muhar, E V Jorgensen, F B Diamond, B B Bercu, A W Root.   

Abstract

We explored our clinical impression that young children with autoimmune hyperthyroidism are more thyrotoxic at presentation and require a longer course of medical therapy than do adolescents to achieve remission. A retrospective chart review of clinical and biochemical data at presentation and response to therapy in 32 prepubertal (PREPUB) and 68 pubertal (PUB) children and adolescents with autoimmune hyperthyroidism was undertaken. Initial therapy included prophylthiouracil or methimazole in all but 11 patients who chose radioactive iodine (131I); 30 additional patients ultimately chose 131I or surgery after an initial period of medical therapy. In PREPUB children there were significantly longer duration of symptoms (7.8+/-7.7 months) and higher serum concentrations of triiodothyronine (T3) 708+/-330 ng/dL) at presentation than in the PUB group (4.7+/-3.4 months; p < .05) (537+/-197 ng/dL; p < .01). Duration of symptoms correlated negatively with chronologic age (r = -0.24; p < .02) but not with T3 or thyroxine (T4) levels (p = .1). PUB children had significantly higher titers of thyroid microsomal antibodies (positive dilution factor 1:6022+/-14572) than did PREPUB children (1:592+/-1226; p < .05). There was a higher familial incidence of thyroid disease in boys (80%) than in girls (64%) (p < .02). The duration of medical therapy was significantly longer (3.5+/-2.9 years) in PREPUB children compared to the PUB group (2.2+/-1.8 years) (p < .05). Only 17% of PREPUB treated 5.9+/-2.8 years compared with 30% of PUB treated 2.8+/-1.1 years achieved a 1-year remission after stopping antithyroid medication (percentage between groups, p < .01; years of treatment, p < .05). The median time to remission after medical therapy was 8 years in PREPUB and 4 years in PUB (p < .02). PREPUB children continued to remit after prolonged medical therapy (>6 years) whereas PUB patients did not. Total treatment length correlated negatively with chronological age (r = -0.26; p < .05) and positively with T4 and T3 concentrations at diagnosis (r = 0.31; p < .01). The diagnosis of hyperthyroidism is delayed in prepubertal children compared to adolescents. This delay may contribute to the higher T3 levels observed in this group at presentation. Prepubertal children also appear to require longer medical therapy to achieve a lower rate of remission, but do continue to remit after prolonged treatment. These differences in response to therapy should be considered when discussing therapeutic options with the family.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349579     DOI: 10.1089/thy.1997.7.755

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  19 in total

1.  Serendipitous identification of Graves' disease in identical twins with polydipsia.

Authors:  Andrea K Goldyn; Erica A Eugster; Todd D Nebesio
Journal:  J Pediatr Endocrinol Metab       Date:  2010-12       Impact factor: 1.634

Review 2.  The treatment of Graves' disease in children and adolescents.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-09-30

3.  Detours on the road to diagnosis of Graves disease.

Authors:  Emily K Sims; Erica A Eugster; Todd D Nebesio
Journal:  Clin Pediatr (Phila)       Date:  2011-08-25       Impact factor: 1.168

Review 4.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

5.  Disease Burden and Outcome in Children and Young Adults With Concurrent Graves Disease and Differentiated Thyroid Carcinoma.

Authors:  Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

6.  Surgical management of pediatric Graves' disease: an effective definitive treatment.

Authors:  Elena Peroni; Maria Rachele Angiolini; Maria Cristina Vigone; Gilberto Mari; Giuseppe Chiumello; Edoardo Beretta; Giovanna Weber
Journal:  Pediatr Surg Int       Date:  2012-04-29       Impact factor: 1.827

Review 7.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

8.  Clinical and endocrine features and long-term outcome of Graves' disease in early childhood.

Authors:  A T Bossowski; V Reddy; L A Perry; L B Johnston; K Banerjee; J C Blair; M O Savage
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

9.  "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.

Authors:  M C Vigone; E Peroni; M Di Frenna; S Mora; G Barera; G Weber
Journal:  J Endocrinol Invest       Date:  2019-11-12       Impact factor: 4.256

Review 10.  Graves disease in childhood: a review of the options for diagnosis and treatment.

Authors:  Jorg Dötsch; Wolfgang Rascher; Helmuth G Dörr
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.